Pretargeting of Astatine-211 for Therapy of Metastic Prostate Cancer
Abstract
The overall purpose of the research project is to develop a new method for treating metastatic prostate cancer. The new method being developed will selectively target the alpha particle-emitting radionuclide astatine-211 to metastatic cancer cells using the antibody-based approach termed "pretargeting". The goal of the first year's research effort was to optimize the reagents used, and timing for their application, in the retargeting protocol using a prostate carcinoma xenograft model (LNCaP) in athymic mice. This goal was largely accomplished, however, some of the results obtained in the biodistribution studies suggest that minor changes in reagents will be required. Along with the synthesis of new reagents for astatine-211 labeling, six biodistribution studies were carried out. The results indicate that very good tumor targeting was obtained, but concentrations of reagents found in liver and spleen were troublesome. Therefore, we will evaluate another antibody and (possibly) another prostate cancer xenograft in continuing studies. Although some changes are anticipated, the research will continue to follow the approved "Statement of Work."
Document Details
- Document Type
- Technical Report
- Publication Date
- Aug 01, 1999
- Accession Number
- ADA374830
Entities
People
- D. S. Wilbur
Organizations
- University of Washington